R&D and Production
Product Pipeline
Diversified, comprehensive and balanced product pipeline developed with a forward-looking, de-risked development approach.
PIPELINE
Cell Therapy
Antibody
Program*
Target
Indications (Line of Treatment)
Pre-clinical
Phase I
Phase II/Phase III
BLA
Commercial Rights
ex vivo CAR-T
Eque-cel
(CT103A)
(CT103A)
BCMA
relapsed/refractory
Multiple Myeloma (r/r MM ≥4L)
Multiple Myeloma (r/r MM ≥4L)
BLA approval
BLA application submitted or accepted
IND (Japan)
r/r MM (2L/3L)
Phase III registrational trial
Newly Diagnosed MM (High-risk 1L)
IIT
Myasthenia Gravis (MG)
IND
IND (USA)
Multiple Sclerosis (MS)
IND (USA)
Systemic Lupus Erythematosus (SLE),
Lupus Nephritis (LN)
Lupus Nephritis (LN)
IND (USA)
MS, SLE, Idiopathic Inflammatory Myopathies (IIM), etc.
IIT
IASO120
CD19/CD22
relapsed/refractory B cell Non-Hodgkin
Lymphoma (r/r B-NHL ≥3L)
Lymphoma (r/r B-NHL ≥3L)
Phase II clinical trial
IASO118
GPRC5D
r/r MM (≥4L)
IND
IASO140
BCMA/GPRC5D
r/r MM (≥4L)
IIT
in vivo CAR-T
IASO206
BCMA
r/r MM (≥4L)
IIT
IASO207
CD19
B-NHL (≥3L) and SLE
IIT
IASO208
CD20
B-NHL (≥3L)
IIT
IASO209
Undisclosed
Undisclosed
Pre-clinical
IASO210
Undisclosed
Undisclosed
Pre-clinical
Antibody
IASO782
CD19
Immune thrombocytopenic
purpura (ITP) and warm autoimmune
hemolytic anemia (wAIHA)
purpura (ITP) and warm autoimmune
hemolytic anemia (wAIHA)
Phase I clinical trial
IND (USA)
SLE
IND
✶Unless otherwise specified, the clinical trial was conducted in China.
Commercialized Product
Mainland China
Macau, China
Hongkong, China
Mainland China
Macau, China
Hongkong, China
Orphan Drug Designation
South Korea
Saudi Arabia
South Korea
Saudi Arabia
Exempted by regulatory authority based on the clinical trials conducted in China
Singapore
Hongkong, China
Saudi Arabia
The United Arab Emirates
Singapore
Hongkong, China
Saudi Arabia
The United Arab Emirates